NCT03883100 - A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

March 31, 2025

Conditions

Chronic Myeloid Leukemia - Accelerated Phase

Interventions

DRUG

HQP1351

40 mg tablet, taken orally once every other day

Trial Locations (9)

Peking University People's Hospital, Beijing

Tongji medical college Huazhong University of Science and Technology, Wuhan

Union Hospital medical college Huazhong University of Science and Technology, Wuhan

Nanfang hospital of southern medical university, Guangzhou

Sun Yat-sen University Cancer Center, Guangzhou

Shenzhen Second People's Hospital, Shenzhen

Henan Tumor Hospital, Zhengzhou

The First Hospital Affiliated of Soochow University, Suzhou

Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin